Pipeline


Elpiscience has a robust pipeline of next-generation cancer immunotherapies, including four clinical-stage programs, focused on removing immunosuppressive factors and reinvigorating exhausted T cells in the tumor microenvironment (TME).


  • Assets with greater China rights
  • Assets with global rights
  • Removing immune suppressive factors in TME
  • Re-invigorating exhausted T cells
  • ES104
    View More
    Target
    VEGF/DLL4
    Discovery Preclinical Ph1 Ph2 Ph3
    Monotherapy
    +chemo
  • ES101
    View More
    Target
    4-1BB/PD-L1
    Discovery Preclinical Ph1 Ph2 Ph3
    Monotherapy/
    Combo
  • ES102
    View More
    Target
    OX40
    Discovery Preclinical Ph1 Ph2 Ph3
    +PD-1
  • ES002
    View More
    Target
    CD39
    Discovery Preclinical Ph1 Ph2 Ph3
    Monotherapy/
    Combo
  • ES014
    View More
    Target
    CD39/TGF-β
    Discovery Preclinical Ph1 Ph2 Ph3
    Monotherapy/
    Combo
  • ES005
    View More
    Target
    LAG3
    Discovery Preclinical Ph1 Ph2 Ph3
    Monotherapy/
    Combo
  • ES004
    View More
    Target
    SIRPα
    Discovery Preclinical Ph1 Ph2 Ph3
    Monotherapy/
    Combo
  • ES009
    View More
    Target
    LILRB2
    Discovery Preclinical Ph1 Ph2 Ph3
    Monotherapy/
    Combo
  • ES028
    View More
    Target
    SIRPα/CLDN18.2
    Discovery Preclinical Ph1 Ph2 Ph3
    Monotherapy/
    Combo